Clinically, resistance to PI3K inhibitors is mediated by insulin feedback caused by hyperglycemic side effects following PI3K inhibition. Paxalisib in combination with the anti-glycemic drug metformin reduced these side effects and improved efficacy in pre-clinical models. (3/11)